In today’s Pharma Pulse, HHS Secretary RFK Jr. centralizes department operations under CMS leadership, while a new telehealth model shows a 66% reduction in repeat ER visits for older adults.

The online pharmacy is collaborating with a digital health provider to combine direct-to-patient GLP-1 dispensing with virtual clinical support, highlighting evolving supply chain and regulatory ...

In the final part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, shares that companies facing the largest revenue gaps from looming patent ...

A 2026 industry survey finds mounting pressure from PBMs, federal pricing reforms, and compliance scrutiny, as manufacturers ...

Pharma’s $372B M&A surge fights a $300B patent cliff, with firms relying on early-stage assets and Chinese innovation to fill gaps by 2030.

In today’s Pharma Pulse, the Senate tackles the regulatory red tape driving physician burnout, while Edwards Lifesciences ends its anti-copycat policy to settle European Commission antitrust concerns.

The approaching patent cliff—projected to expose as much as $300 billion in annual drug sales to loss of exclusivity by 2032—is expected to keep pharmaceutical M&A activity active in 2026, but not ...

In today’s Pharma Pulse, Eli Lilly amasses a record-breaking stockpile for its oral GLP-1, while new research reveals a 66% reduction in endometrial cancer risk for certain patients.

In the second part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, suggests that 2026 pharma M&A may fall short of last year’s $220 billion ...

The Inflation Reduction Act (IRA) promised big changes for Medicare Part D beneficiaries. Beginning in 2026, patients’ annual out-of-pocket (OOP) costs for Part D drugs are capped at $2,100, and the ...